Saturday 17 October 2026
Export SANA’s income statement to Excel — free account
Sana Biotechnology, Inc.
SANA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 43.6% and free cash flow fell 5.46%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
2.27
0.21
−8.47%
Follow SANA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
1.89 | 3.54 | 3.31 | 3.99 | 5.62 | 12.22 | 7.47 | 16.50 | — |
Net Debt/EBITDA |
0.60 | 0.61 | 0.76 | 1.67 | 1.59 | 1.35 | 1.00 | 3.77 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.59 | 0.84 | 0.90 | 1.08 | 0.71 | 0.48 | 0.65 | 1.02 | — |
Capex/Depreciation |
0.04 | (2.16) | (1.14) | (1.34) | (2.70) | (4.03) | (14.31) | 0.00 | — |
| (118.70%) | (99.17%) | (72.00%) | (43.90%) | (231.64%) | 101.22% | 168.16% | 16.98% | — | |
| (53.20%) | (50.03%) | (40.81%) | (27.61%) | (38.28%) | (49.81%) | (58.23%) | (77.92%) | — | |
ROIC |
(854.59%) | (180.99%) | (233.45%) | (245.99%) | (125.67%) | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(252.09%) | (138.44%) | (128.92%) | (67.39%) | (67.88%) | (71.36%) | (85.56%) | (41.40%) | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.48 | 0.40 | 0.35 | 0.24 | 0.18 | 0.27 | 0.48 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(0.57) | (1.11) | (1.41) | (1.65) | (1.69) | (12.44) | (22.77) | (0.07) | — |
Cash per Share |
0.56 | 0.68 | 1.07 | 2.28 | 3.31 | 29.07 | 28.35 | 0.17 | — |
Shareholders Equity per Share |
0.64 | 1.08 | 1.48 | 2.65 | 4.38 | (32.36) | (29.07) | 0.18 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.64 | 1.08 | 1.48 | 2.65 | 4.38 | (32.36) | (29.07) | 0.18 | — |
Free Cash Flow |
(143.33) | (256.58) | (273.61) | (310.93) | (280.92) | (161.85) | (111.64) | (13.49) | — |
Working Capital |
69.95 | 115.38 | 149.03 | 332.93 | 458.87 | 353.02 | 124.94 | 31.00 | — |
Capital Expenditures |
0.49 | (33.43) | (20.03) | (20.88) | (29.86) | (23.87) | (26.12) | (0.46) | — |
Net Current Asset Value |
(107.33) | (89.71) | (64.28) | 121.03 | 157.20 | (767.01) | (413.47) | 31.00 | — |
| Other line items | |||||||||
Quick Ratio |
1.81 | 3.44 | 3.24 | 3.86 | 5.55 | 12.03 | 7.19 | 15.50 | — |
Depreciation/Fixed assets |
0.47 | 0.20 | 0.25 | 0.23 | 0.17 | 0.13 | 0.07 | 0.00 | — |
Cash ROIC |
(47.23%) | (63.07%) | (55.10%) | (33.46%) | (21.96%) | 377.11% | 3,136.01% | (21.09%) | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.57) | (0.97) | (1.30) | (1.54) | (1.51) | (10.60) | (17.44) | (0.07) | — |
Capex per Share |
0.00 | (0.14) | (0.10) | (0.11) | (0.18) | (1.83) | (5.33) | 0.00 | — |
Average Payables |
3.44 | 4.66 | 3.48 | 2.54 | 2.24 | 0.92 | (0.21) | (0.21) | — |
Average Assets |
458.96 | 533.16 | 694.01 | 976.06 | 929.85 | 572.74 | 224.60 | 17.00 | — |
Average Common Equity |
205.69 | 269.01 | 393.41 | 613.91 | 153.66 | (281.86) | (77.77) | (78.00) | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Columns are period end dates